A poptosis plays a critical pathogenic role in many cardiovascular diseases, including myocardial ischemia/reperfusion (MI/R) and heart failure. 1 Under physiological conditions, apoptosis is tightly controlled by a balance between proapoptotic and antiapoptotic molecules. Because a majority of the signaling molecules involved in apoptosis are proteins, the normal balance between these forces can be destroyed not only at the gene level (transcriptional regulation) but also at the protein level (posttranslational modification). Substantial evidence exists that posttranslational protein phosphorylation/dephosphorylation plays a critical role in regulating apoptotic signaling. Interventions that modulate protein phosphorylation/dephosphorylation (eg, kinase inhibitors or activators) have been proposed in the treatment of cardiovascular diseases.
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Thioredoxin (Trx) is a small protein expressed in all living cells. 2 Clinical and experimental results have demonstrated that Trx is markedly upregulated in cancer tissues, and molecules that inhibit Trx promote apoptosis and reduce cancer development. 3 On the other hand, genetic inhibition of endogenous Trx in the heart increases oxidative stress, 4 and acute inhibition of Trx abolishes preconditioning-induced cardiac protection. 5 Moreover, Trx-deficient cells show an accumulation of intracellular reactive oxygen species (ROS) and mitochondriadependent apoptosis, and genetic ablation of Trx in mice causes massively increased apoptosis in embryos on embryonic day 10.5 (E10.5), leading to embryonic lethality. 6, 7 Conversely, overexpression of Trx confers resistance to ROS-induced cell death. 8 -10 These results demonstrate that Trx plays a critical role in cell proliferation/cell death. Recent in vitro studies have demonstrated that Trx interacts directly with and inhibits the activity of apoptosis signal-regulating kinase-1 (ASK1), a mitogen-activated protein kinase (MAPK) kinase that activates 2 proapoptotic kinases, p38 MAPK and JNK (Jun n-terminal kinase), 11, 12 thus exerting its potent antiapoptotic effect. Unlike the case of its downstream molecules (eg, ASK1 and p38 MAPK), Trx activity is not regulated by protein phosphorylation. In addition, a recent in vitro study has demonstrated that Trx promotes ASK1 ubiquitination and degradation to inhibit ASK1-mediated apoptosis in a redox activity-independent manner. 12 Therefore, despite its critical regulatory role in apoptosis signaling, regulation of the antiapoptotic activity of Trx remains unclear.
The nitration of protein tyrosine residues (addition of an nitro [ϪNO 2 ] group) has been used extensively as a footprint for in vivo production of reactive nitrogen species, particularly peroxynitrite (ONOO Ϫ ). 13 However, emerging evidence indicates that protein nitration is a novel form of posttranslational modification that may play a critical role in physiological and pathological signalings. 14 -16 Several recent studies utilizing proteomic approaches have demonstrated that multiple intracellular proteins involved in oxidative stress and apoptosis are nitrated in the diabetic heart 17 and in inflammatory lungs 18 but not in normal tissues. However, the contribution of these nitrated proteins to diabetic or inflammatory tissue injury remains unclear. Moreover, recent in vitro studies have demonstrated that nitrative modification of a number of cytoprotective molecules, including superoxide dismutase (SOD) 19, 20 and prostacyclin synthase, 21 results in their enzymatic inactivation. However, definitive evidence that supports a causative link between nitrative inactivation of a specific protein with tissue injury in a specific disease is currently lacking. Therefore, the aims of the present study were (1) to determine whether Trx is susceptible to nitrative modification in vitro and in vivo; (2) to investigate the functional consequence of Trx nitration; and (3) to establish a causative link between Trx nitration and postischemic myocardial apoptosis.
Methods

In Vitro Nitration of Trx-1
Human Trx-1 (the cytosolic form of Trx, Sigma Chemical Co, St Louis, Mo) was subjected to in vitro nitration with a modified procedure recently described by Guo and colleagues for MnSOD nitration. 19 In brief, purified human Trx-1 (dissolved in 0.1 mol/L phosphate buffer, pH 7.4, final concentration 50 mol/L) was incubated with 3-morpholinosydnonimine (SIN-1; final concentration 100 mol/L, Cayman Chemical, Ann Arbor, Mich) at 37°C for 30 minutes in the presence and absence of MnTE-2-PyP 5ϩ (500 mol/L), a cellpermeable superoxide dismutase (SOD) mimetic (kindly provided by Dr Batinic-Haberle, Duke University, Durham, NC). Unreacted SIN-1 was removed by ultrafiltration over membranes with a 5-kDa cutoff. Samples were electrophoretically size-fractionated on sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto a polyvinylidene diflouride-plus membrane, and nitrated Trx-1 was detected with anti-nitrotyrosine antibody.
Trx-1 Activity Assay
Trx-1 activity was determined with the insulin disulfide reduction assay 4 and expressed as nicotinamide adenine dinucleotide phosphate oxidized (mol) per minute per milligram of protein.
Comparison of the Cardioprotective Effects of Reduced and Nitrated Trx-1
Male adult mice were anesthetized with 2% isoflurane. Myocardial ischemia was produced by temporarily exteriorizing the heart via a left thoracic incision and placing a 6-0 silk suture slipknot around the left anterior descending coronary artery. After 30 minutes of ischemia, the slipknot was released, and the myocardium was reperfused for 3 hours (for apoptosis) or 24 hours (for infarct size). Ten minutes before reperfusion, mice were randomized to receive either vehicle (phosphatebuffered saline, pH 7.5), reduced Trx-1 (Trx-1, 2 mg/kg), 22 or nitrated Trx-1 (N-Trx-1) by intraperitoneal injection. The effects of reduced or nitrated Trx-1 on myocardial apoptosis (DNA ladders, terminal dUTP nick end-labeling [TUNEL] staining, and caspase-3 activity assay) and myocardial infarction (Evans blue/TTC double staining) were determined as described previously. 22 Detection of Trx-1 Nitration and Trx-1/ASK1 Interaction in the Ischemic/Reperfused Heart Ischemic/reperfused (30 minutes/3 hours) cardiac tissue was homogenized with lysis buffer. Immunoprecipitation and immunoblotting were performed by a procedure described by Vadseth and colleagues. 23 In brief, endogenous Trx-1 was immunoprecipitated with a monoclonal anti-murine Trx-1 antibody (Redox Bioscience, Kyoto, Japan). After sample separation, Trx-1 nitration was detected with a monoclonal antibody against nitrotyrosine (Upstate, Charlottesville, Va), and Trx-1/ ASK1 interaction was determined with a polyclonal antibody against ASK1 (Upstate). The blot was developed with Supersignal-Western reagent (Pierce, Rockford, Ill) and visualized with a Kodak Image Station 400 (Eastman Kodak Co, Rochester, NY). Blot densities were analyzed with Kodak 1D software (version 3.6).
p38 MAPK Activity Assay
The p38 MAPK activity assay was performed with a p38 MAPK assay kit (Cell Signaling Technology, Danvers, Mass) with activating transcription factor-2 as a substrate as described in our previous study. 24 
Tyrosine Mutagenesis
Site-directed mutagenesis of human Trx-1 (tyrosine-49 to phenylalanine) was performed with a QuikChange Mutagenesis kit (Stratagene, La Jolla, Calif) according to the manufacturer's instructions. Primers used to construct Y49F mutant have the sequences 5-GGA ATA TCA CGT TGG AAA ACT TTT CAG AGA GGG -3 and its reverse complement. The mutations were confirmed by DNA sequencing.
Statistical Analysis
All values in the text and figures are presented as meanϮSEM of n independent experiments. All data (except Western blot density) were subjected to ANOVA followed by Bonferroni correction for post hoc t test. Western blot densities were analyzed with the Kruskal-Wallis test followed by Dunn post hoc test. Probabilities of 0.05 or less were considered to be statistically significant.
The authors had full access to the data and take full responsibility for their integrity. All authors have read and agree to the manuscript as written.
Results
Trx-1 Is Susceptible to Nitrative Modification and Its Activity Irreversibly Inhibited
Protein nitration has been shown to be a selective posttranslational protein modification process, and it has been shown that not all tyrosine-containing proteins are susceptible to nitration. 15 Previous molecular and structural studies have demonstrated that unlike bacteriophage-and Escherichia coli-produced Trx-1 (which contain 5 and 2 tyrosine residues, respectively), human Trx-1 only contains 1 tyrosine (Tyr 49 ). 25 To determine whether the single-tyrosine-containing human Trx-1 is susceptible to nitrative modification, purified human Trx-1 was incubated with SIN-1, a molecule that simultaneously generates nitric oxide and superoxide, thus functioning as a peroxynitrite donor, and Trx-1 nitration was determined by Western blot with a monoclonal antibody against nitrotyrosine. As illustrated in Figure 1A , exposure of Trx-1 to SIN-1 (lane 1) resulted in significant Trx-1 nitration, which was completely blocked when a superoxide scavenger was added at 5 times higher concentration than SIN-1 (lane 2). Moreover, SIN-1-induced Trx-1 nitration was completely abolished when tyrosine-49 was replaced with phenylalanine (lane 4). These results indicate that although human Trx-1 only contains a single tyrosine, it can be nitrated in an ONOO Ϫ -dependent manner.
Haendeler and colleagues 26 and our group 22 have previously demonstrated that incubation of human Trx-1 with 100 mol/L S-nitrosoglutathione, an NO donor, results in Trx-1 S-nitrosylation at cysteine-69. To determine whether incubation of Trx-1 with SIN-1 at the same concentration (ie, 100 mol/L) may also induce Trx-1 S-nitrosylation, we used the same method as that used in our previous study and determined Trx-1 S-nitrosylation. Our results demonstrated that incubation of Trx-1 with 100 mol/L SIN-1 at room temperature for 30 minutes failed to cause significant Trx-1 S-nitrosylation (data not shown). This result is consistent with that reported by Mohr et al 27 demonstrating that although glyceraldehyde phosphate dehydrogenase can be S-nitrosylated by SIN-1, this reaction requires much a higher concentration of SIN-1 (800 mol/L) and a much longer incubation time (40 minutes) than that induced by a pure NO donor (200 mol/L and 2.5 minutes). These results demonstrated that peroxynitrite is a strong nitrating agent but a weak nitrosylation molecule.
Having demonstrated that Trx-1 is susceptible to nitration, we further determined whether the activity of Trx-1 is altered by this posttranslational modification. As summarized in Figure 1B , treatment with SIN-1 almost completely inactivated Trx-1 (PϽ0.001). Coincubation with MnTE-2-PyP 5ϩ (to remove SIN-1-released O 2 -⅐ ) completely and coincubation with nitric oxide scavenger PTIO (to remove SIN-1-released NO; AG Scientific, San Diego, Calif) markedly blocked SIN-1-induced inactivation of Trx-1. Because Trx-1 was incubated with dithiothreitol (DTT) after SIN-1 exposure, this SIN-1 induced Trx-1 inactivation cannot be explained by oxidative Trx-1 inhibition. Moreover, preincubation of H 2 O 2 -treated Trx-1 with DTT reducing buffer resulted in complete recovery of Trx-1 activity (data not shown). Therefore, our results strongly suggest that a nitrative protein modification rather than oxidative modification is responsible for SIN-1-induced Trx-1 inactivation. In addition, this result also provided clear evidence that ONOO Ϫ , but not NO or O 2 -⅐ , is responsible for nitrative inactivation of Trx-1.
Nitrative Inactivation of Trx-1 Blocks Its Antiapoptotic and Cardioprotective Effects
We 22 and others 28 have recently demonstrated that administration of recombinant human Trx-1 (rhTrx-1) to animals subjected to MI/R or to autoimmune myocarditis exerts significant cardioprotective effects. Having demonstrated that nitrative modification resulted in its inactivation in vitro, we further investigated whether Trx-1 nitration may also abolish its antiapoptotic and cardioprotective effect in vivo. Consistent with our previous finding, treatment with reduced Trx-1 exerted significant cardioprotective effects, as evidenced by decreased TUNEL-positive nuclei (Figure 2 ), attenuated DNA ladder formation ( Figure 3A) , reduced caspase-3 activity ( Figure 3B ), and decreased infarct size ( Figure 4) . However, exposure of Trx-1 to SIN-1 before its administration (N-Trx-1) completely blocked its cardioprotective effect (Figures 2 through 4) . To obtain more evidence that SIN-1 inhibits Trx-1 activity by nitrative modification, 2 additional experiments were performed. First, a mutant form of Trx-1 (Trx-Y49F; tyrosine replaced with phenylalanine) was preincubated with phosphate-buffered saline or SIN-1 for 30 minutes and administered ( 2 mg/kg IP) 10 minutes before reperfusion. Their effect on postischemic myocardial apoptosis was determined by caspase-3 activity assay. As illustrated in Figure 3 , administration of Trx-Y49F significantly reduced cardiomyocyte apoptosis. Most importantly, exposure of this nitrative-resistant mutant form of Trx-1 to SIN-1 before its in vivo administration failed to abolish its cardioprotective effect. Second, Trx-1 was preincubated with H 2 O 2 (100 mol/L) for 30 minutes, and this oxidized form of Trx-1 (2 mg/kg) was administered 10 minutes before reperfusion. Our experimental results demonstrated that administration of this oxidized Trx significantly reduced myocardial infarct size (Figure 4) , which indicates that exogenously administered oxidized Trx can be , resulted in a complete loss of its infarct reduction effect when administered in vivo. Top, Representative photographs of heart sections. Black-stained portion indicates nonischemic, normal region; red-stained portion, ischemic/reperfused but not infarcted region; and negative-stained portion, ischemic/reperfused infarcted region. Bottom, Summary of myocardial infarct size expressed as a percent of total ischemic-reperfused area (area-at-risk, AAR). nϭ12 mice/group. **PϽ0.01 vs vehicle-treated ischemic/reperfused hearts.
Trx-1 is nitratively modified and its activity inhibited in vivo after MI/R. A group of mice was subjected to 30 minutes of myocardial ischemia followed by 3 hours of reperfusion (MI/R).
Trx-1 nitration was determined by anti-Trx-1 immunoprecipitation followed by antinitrotyrosine immunoblotting. As illustrated in Figure 5A , nitrated Trx-1 was not detected in cardiac samples from sham MI/R animals. In contrast, 30 minutes of ischemia followed by 3 hours of reperfusion resulted in significant Trx-1 nitration. Consistent with the nitrative Trx-1 modification by ischemia/reperfusion, Trx activity in ischemic/reperfused cardiac tissue was significantly reduced compared with that of tissues isolated from sham MI/R animals ( Figure 5B ).
Downstream Signaling Mechanisms by Which Trx-1 Nitration May Induce Cardiomyocyte Apoptosis
Recent in vitro studies have demonstrated that binding/inhibition of Trx-1 with ASK1 is the primary mechanism by which Trx-1 exerts its antiapoptotic effect. 11, 12 To determine whether Trx-1 nitration may alter the Trx-1/ASK1 interaction, thus activating the downstream proapoptotic kinase, 2 additional observations were made. As illustrated in Figure 6 , Trx-1 is physically associated with ASK-1 (anti-Trx-1 immunoprecipitation and anti-ASK1 immunoblotting) in cardiac tissues from sham MI/R animals. However, this protein/protein interaction was virtually abolished in ischemic/reperfused cardiac tissue. Consequently, a Ͼ12-fold increase in p38 MAPK activity, a downstream molecule by which ASK1 exerts its proapoptotic effect, was observed in the ischemic/reperfused heart ( Figure 7A and 7B).
Blockade of Trx Nitration Protected the Heart From Ischemia/Reperfusion Injury
Considerable evidence exists that peroxynitrite is the most pathologically relevant nitrating agent in vivo. To obtain more evidence to support our hypothesis that Trx-1 nitration is causatively related to postischemic myocardial apoptosis, mice were treated with either FP-15 (5 mg/kg, 10 minutes before reperfusion; Inotek Pharmaceuticals Corp, Beverly, Mass), a novel peroxynitrite decomposition catalyst, 29 or MnTE-2-PyP 5ϩ (25 g/kg), a cell-permeable SOD mimetic. 30 Impressively, treatment with FP-15 or MnTE-2-PyP 5ϩ shortly before reperfusion blocked Trx-1 nitration (Figure 5A ), preserved Trx activity ( Figure 5B ), maintained Trx-1 binding activity with ASK1 (Figure 6 ), attenuated p38 MAPK activation ( Figure 7A and 7B), and reduced postischemic myocardial apoptosis ( Figure  7C ). These results provided strong evidence that peroxynitriteinduced Trx nitration plays a causative role in postischemic cardiomyocyte apoptosis.
Discussion
We have made several novel observations in the present study. First, we have demonstrated for the first time that mammalian Trx-1, a single-tyrosine-containing molecule that has been shown to play an essential role in promoting cell survival, is susceptible to posttranslational nitrative modification. Second, we have provided the first evidence that nitrative modification inhibits Trx-1 activity in vitro and abolishes its cardioprotective effects in vivo. These results strongly suggest that with nitrative inactivation, Trx-1 may lose its antiapoptotic and cytoprotective property under those pathological conditions in which production of nitrating molecules (eg, ONOO Ϫ ) is increased, thus contributing to cell death and tissue injury. Third, we have demonstrated that nitrative modification of Trx-1 results in its dissociation from ASK1 and subsequent ASK1 activation. This result identified a novel signaling mechanism by which reactive nitrogen species causes apoptotic cell death. Finally, we have demonstrated that in vivo MI/R resulted in significant Trx-1 nitration and inactivation. Treatment with a novel peroxynitrite decomposition catalyst shortly before reperfusion blocked nitra- 
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tive Trx-1 inactivation, attenuated ASK1 activation, and reduced postischemic myocardial apoptosis. Although numerous studies have demonstrated that nitrotyrosine content is markedly increased in a variety of diseased tissues, the present study provided the first direct evidence that links nitrative modification of a specific protein with apoptotic cell death in the ischemic/ reperfused heart. The Trx system, including Trx, Trx reductase (TrxR), Trx peroxidase, and nicotinamide adenine dinucleotide phosphate, is a ubiquitous thiol oxidoreductase system that regulates cellular reduction/oxidation (redox) status and cell proliferation/cell survival. Two isoforms of Trx and TrxR have been identified in mammalian cells: cytosolic Trx-1/TrxR-1 and mitochondrial Trx-2/TrxR-2. Emerging evidence suggests that Trx plays a critical role in promoting cell proliferation/survival and reducing cell death. Trx and TrxR are markedly upregulated in cancer tissues, and molecules that inhibit Trx or TrxR promote apoptosis and reduce cancer development. 31 In contrast, Trx-1 activity is markedly reduced in diseased tissues in which pathological apoptosis is increased. 2, 32 Moreover, transgenic mice overexpressing Trx-1 or Trx-2 demonstrate resistance to ROS-induced cell death, and pharmacological supplementation of exogenous Trx-1 confers such resistance 8 -10 and reduces tissue injury. 33 In contrast, genetic ablation of Trx-1 or Trx-2 expression increases oxidative stress, 4,5 stimulates mitochondria-dependent apoptosis, and causes massive tissue injury. 6, 7 Cumulatively, these data strongly suggest that altered Trx expression and/or activity play critical pathogenic roles in human diseases and that Trx may be a novel therapeutic target for those diseases, such as cardiovascular disease, in which a physiological balance between cell death and cell proliferation is disturbed.
Recent studies have demonstrated that in addition to upregulation or downregulation of Trx expression at the gene level, Trx activity is regulated by posttranslational modification. Three forms of posttranslational modifications of Trx have been identified previously. These include oxidation, glutathionylation, and S-nitrosylation. Interestingly, all 3 forms of modification occur at cysteine residues but affect Trx function differently. Oxidation of the thiol groups of Cys-32 and -35 forms a disulfide bond that results in Trx inactivation. Glutathionylation occurs at Cys-73, and this posttranslational modification significantly inhibits Trx activity. 34 S-nitrosylation occurs selectively at Cys-69. In contrast to oxidation and glutathionylation, S-nitrosylation markedly enhances Trx activity. 22, 26, 35 In the present study, we have demonstrated for the first time that in addition to previously reported posttranslational Trx-1 modification that occurs at the cysteine residue, Trx-1 can also be modified at the tyrosine residue (protein nitration). Previous molecular and structural studies have demonstrated that, like cysteine, the content of tyrosine differs in different forms of Trx-1. Trx-1 from bacteriophage T4 contains 5 tyrosine residues, and 1 of them is located within its redox active center. 36 Trx-1 produced by E coli contains 2 tyrosine (Tyr 49 and Tyr
70
) residues. Interestingly, mammalian Trx-1 only contains 1 tyrosine (Tyr 49 ), and it is located within a region that is critical for Trx-1 folding. 25, 37, 38 Because the function of Trx-1 critically depends on its proper folding, 39,40 the present results strongly suggest that nitration of Tyr 49 is a novel posttranslational modification that inhibits Trx-1 function by conformational change.
Previous biochemical studies have demonstrated that nitration often occurs with oxidation. In addition, we have observed that exposure of Trx to a peroxynitrite donor results in its functional inhibition, similar to that reported for Trx-1 oxidation. However, the present results strongly suggest that nitration is a novel posttranslational modification that regulates Trx-1 activity independent of oxidation. First, our in vitro study demonstrated that preincubation of H 2 O 2 -treated Trx-1 with DTT resulted in a complete recovery of its activity (data not shown). However, preincubation of SIN-1-treated Trx-1 with DTT failed to recover its activity. Second, previous studies have demonstrated that administration of oxidized Trx-1 exerts significant antioxidant and cytoprotective effects unless intracellular TrxR is inhibited, which suggests that exogenous oxidized Trx-1 is reduced by TrxR, with resultant recovery of its biological function. 41, 42 However, the present study demonstrated that administration of nitrated Trx-1 failed to exert antiapoptotic and cardioprotective effects in the ischemic/reperfused heart, which indicates that nitration of Trx-1 resulted in an irreversible inhibition of its biological function. This result also suggested that a previously proposed "nitrotyrosine dinitrase" 43 either does not exist in adult cardiomyocytes or its function is inhibited after ischemia/reperfusion. Further study to address this important question is warranted.
ASK1 is an MAPK kinase that functions as an upstream activator of JNK and p38 MAPK. Under physiological conditions, ASK1 activity is inhibited by several cellular factors, including Trx, glutaredoxin, and phosphoserine-binding protein 14-3-3. 44 Trx-1 binds to the N-terminal domain of ASK1 with its cysteine 32 and/or 35 to inhibit ASK1 kinase activity, whereas glutaredoxin binds to the C-terminal domain of ASK1 to inhibit ASK1 kinase activity. 11,45 14-3-3 associates with ASK1 via the pSer 967 site of ASK1 and inhibits ASK1-induced apoptosis. 46 Previous studies have demonstrated that many cellular stress and apoptotic stimuli activate mitochondria-dependent apoptotic pathways by facilitating dissociation of ASK1 with its inhibitory proteins. Specifically, tumor necrosis factor-␣ has been reported to stimulate apoptosis by dissociating ASK1 from 14-3-3. 47 Hyperglycemia has been shown to stimulate endothelial apoptosis by upregulating the expression of Trx-interacting protein (also termed vitamin D 3 -upregulated protein) and inducing dissociation of ASK1 from Trx-1. 48 Recent in vitro studies have demonstrated that ROS results in Trx oxidation and subsequent dissociation from ASK1, thus facilitating apoptotic cell death. 49 However, oxidized Trx can be reduced by Trx reductase and its ASK1 binding ability fully recovered. Moreover, administration of oxidized Trx-1 exerts significant antioxidant and cytoprotective effects unless intracellular TrxR is inhibited. 41, 42 Therefore, the in vivo pathological relevance of ASK1 activation by oxidative Trx-1 inactivation remains questionable. The present study demonstrated that nitrative modification of Trx-1 also resulted in its dissociation from ASK1 and subsequent ASK1 activation. Because an effective "denitration" system does not exist in adult cardiomyocytes, nitrated Trx-1 cannot be reactivated. Moreover, substantial evidence exists that production of reactive nitrogen species, particularly peroxynitrite, is markedly increased in a variety of diseased tissues. The results of the present study thus strongly suggest that nitrative Trx-1 modification is a novel pathological pathway by which reactive nitrogen species result in ASK1 activation and subsequent cardiomyocyte apoptosis.
Although numerous studies have been published demonstrating that protein nitration is increased in diseased tissues, we have identified a single protein that is nitrated in the ischemic/ reperfused heart and have linked its nitrative inactivation with postischemic cardiomyocyte apoptosis, a primary form of cell death that is responsible for reperfusion injury. The present experimental results have broad clinical implications. Therapeutic interventions that inhibit Trx-1 nitration may have application in those diseases in which pathological apoptosis is increased, such as MI/R injury and neurological disorders. In contrast, promotion of posttranslational Trx-1 modification (nitration) may be a better approach than gene therapy (inhibition of Trx expression) for the treatment of cancer in which Trx expression is increased and physiological apoptosis is inhibited.
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CLINICAL PERSPECTIVE
Apoptosis plays a critical pathogenic role in many cardiovascular diseases, including myocardial ischemia/reperfusion and heart failure. Identifying the signaling pathways that lead to myocardial apoptosis may open a new door toward preventing cardiomyocyte death and improving cardiac function in patients with cardiovascular diseases. Thioredoxin (Trx) is a small protein expressed in all living cells. Previous clinical results have demonstrated that Trx is markedly upregulated in cancer tissues, and molecules that inhibit Trx promote apoptosis and reduce cancer development, which suggests that Trx is a powerful antiapoptotic/cell-surviving molecule. Here, we have demonstrated for the first time that Trx is susceptible to nitrative modification and that this posttranslational modification inhibits Trx-1 activity in vitro and abolishes its cardioprotective effects in vivo. Additional studies demonstrated that nitrative modification of Trx-1 results in its dissociation from apoptosis signal-regulating kinase-1 (ASK1) and subsequent ASK1 activation. This result identified a novel signaling mechanism by which reactive nitrogen species cause apoptotic cell death. Finally, we have demonstrated that treatment with a peroxynitrite decomposition catalyst shortly before reperfusion blocked myocardial ischemia/ reperfusion-induced nitrative Trx-1 inactivation, attenuated ASK1 activation, and reduced postischemic myocardial apoptosis. The current experimental results have broad clinical implications. Therapeutic interventions that inhibit Trx-1 nitration may have application in those diseases in which pathological apoptosis is increased, such as myocardial ischemia/reperfusion injury and neurological disorders. In contrast, the promotion of posttranslational Trx-1 modification (nitration) may be a better approach than gene therapy (inhibition of Trx expression) for the treatment of cancer in which Trx expression is increased and physiological apoptosis is inhibited.
